Publication | Closed Access

Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts

Dose SchedulingOncologyRadiation TherapyMedicineHead And Neck CancerNeck Tumor XenograftsClinical Radiation OncologyPharmacologyRadiation OncologyTumor BiologyDual Vegfr